Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

Major medtech companies are preparing for significant financial headwinds as tariffs threaten to disrupt the $200 billion | ...

Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

OSE Immunotherapeutics has shared survival data behind a therapeutic vaccine’s phase 2 pancreatic cancer win as the French ...

Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell ...

Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

The Trump administration's proposed funding cuts to the National Institutes of Health (NIH), including the National Cancer ...

The clinical trial tech companies Medidata and Medable are both taking to the floor of the American Society of Clinical ...

The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...